N@N

Andrew Mok Upgraded (THC) to Strong Buy and Increased Target to $111 on, Feb 10th, 2022

Andrew Mok of UBS, Upgraded "Tenet Healthcare Corporation" (THC) to Strong Buy and Increased Target from $83 to $111 on, Feb 10th, 2022.

Andrew has made no other calls on THC in the last 4 months.

There are 10 other peers that have a rating on THC. Out of the 10 peers that are also analyzing THC, 1 agrees with Andrew's Rating of Hold. Following is the relevant analyst calls for the last 4 months

---

• Scott Fidel of "Stephens & Co." Maintained at Hold with Increased Target to $92 on, Tuesday, November 9th, 2021

These are the ratings of the 9 analyists that currently disagree with Andrew

---

• A.J. Rice of "Credit Suisse" Maintained at Buy with Increased Target to $111 on, Wednesday, February 9th, 2022
• David Macdonald of "Truist Securities" Upgraded from Hold to Strong Buy and Held Target at $90 on, Wednesday, February 9th, 2022
• Pito Chickering of "Deutsche Bank" Maintained at Strong Buy with Increased Target to $100 on, Wednesday, February 9th, 2022
• Sarah James of "Barclays" Maintained at Buy with Increased Target to $99 on, Wednesday, February 9th, 2022
• Whit Mayo of "SVB Leerink" Upgraded from Hold to Buy and Increased Target to $100 on, Wednesday, February 9th, 2022
• John Ransom of "Raymond James" Upgraded from Buy to Strong Buy and Increased Target to $120 on, Thursday, January 20th, 2022
• Ann Hynes of "Mizuho" Maintained at Strong Buy with Increased Target to $90 on, Wednesday, November 10th, 2021
• Jason Cassorla of "Citigroup" Maintained at Strong Buy with Increased Target to $91 on, Monday, October 25th, 2021
• Jonathan Yong of "Credit Suisse" Maintained at Buy with Increased Target to $95 on, Friday, October 22nd, 2021

Contributing Sources

---